Hey Hawkbar33, Yep it's value at the moment. Don't blink, as we're already well into March. IMU's management fully know data has to drop in the next few months. I've likened it to a game of musical chairs in the past, which happened on November 6th 2023. Data hasn't flowed on since then, and has been pushed back twice now. Its now been 16 months with retail investors copping a blood bath, progressively since then. So what's a few more months, compared to how long we've already waited. The data or any partnerships, management have already acknowledged as being the only way of seeing a re-rate in the share price.
Such a re-rate is crucial to IMU's future. IMU have capital till at least 2026, with it being pertinent to have at least two quarters being held, with ASX requirements. So that enforces, data dropping in assisting this by at latest June 30th. Good news with Yuman Fong's podcast earlier today. I agree with posters here, that it doesn't cut it, in comparison to ASX price sensitive announcements. However, most here regard his integrity and it adds faith to the science progressing. Also great to see an additional Complete response, with three sites in Australia now recruiting patients.
With regards to Prof Richard Scolyer, my deepest sympathies go out to him and his family. He would have knowledge of IMU, and all other start-up oncology companies, conducting studies. I'm not sure if brain tumor's are part of what IMU's viruses can target just yet, as I simply don't have the knowledge. It would be great to hear back from other medically knowledge posters, in getting some idea.
-GO IMU!
Not Financial Advice - Opinions Only - DYOR!
IMU Price at posting:
3.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)